Cara Therapeutic
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.85
- Today's High:
- $5.09
- Open Price:
- $5.01
- 52W Low:
- $4.85
- 52W High:
- $13.965
- Prev. Close:
- $5.06
- Volume:
- 493951
Company Statistics
- Market Cap.:
- $296.44 million
- Book Value:
- 2.951
- Revenue TTM:
- $41.87 million
- Operating Margin TTM:
- -209.08%
- Gross Profit TTM:
- $-56141000
- Profit Margin:
- -204.16%
- Return on Assets TTM:
- -25.49%
- Return on Equity TTM:
- -44.25%
Company Profile
Cara Therapeutic had its IPO on 2014-01-31 under the ticker symbol CARA.
The company operates in the Healthcare sector and Biotechnology industry. Cara Therapeutic has a staff strength of 106 employees.
Stock update
Shares of Cara Therapeutic opened at $5.01 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $4.85 - $5.09, and closed at $4.92.
This is a -2.77% slip from the previous day's closing price.
A total volume of 493,951 shares were traded at the close of the day’s session.
In the last one week, shares of Cara Therapeutic have slipped by -14.88%.
Cara Therapeutic's Key Ratios
Cara Therapeutic has a market cap of $296.44 million, indicating a price to book ratio of 3.3987 and a price to sales ratio of 15.2232.
In the last 12-months Cara Therapeutic’s revenue was $41.87 million with a gross profit of $-56141000 and an EBITDA of $-87287000. The EBITDA ratio measures Cara Therapeutic's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cara Therapeutic’s operating margin was -209.08% while its return on assets stood at -25.49% with a return of equity of -44.25%.
In Q4, Cara Therapeutic’s quarterly earnings growth was a positive 0% while revenue growth was a positive 297.2%.
Cara Therapeutic’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.42 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cara Therapeutic’s profitability.
Cara Therapeutic stock is trading at a EV to sales ratio of 12.0452 and a EV to EBITDA ratio of -5.3062. Its price to sales ratio in the trailing 12-months stood at 15.2232.
Cara Therapeutic stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $182.24 million
- Total Liabilities
- $23.46 million
- Operating Cash Flow
- $44.42 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Cara Therapeutic ended 2023 with $182.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $182.24 million while shareholder equity stood at $158.78 million.
Cara Therapeutic ended 2023 with $0 in deferred long-term liabilities, $23.46 million in other current liabilities, 53000.00 in common stock, $-566232000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $63.74 million and cash and short-term investments were $145.40 million. The company’s total short-term debt was $1,918,000 while long-term debt stood at $0.
Cara Therapeutic’s total current assets stands at $168.91 million while long-term investments were $11.35 million and short-term investments were $81.66 million. Its net receivables were $3.76 million compared to accounts payable of $21.54 million and inventory worth $2.38 million.
In 2023, Cara Therapeutic's operating cash flow was $44.42 million while its capital expenditure stood at $0.
Comparatively, Cara Therapeutic paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $4.92
- 52-Week High
- $13.965
- 52-Week Low
- $4.85
- Analyst Target Price
- $23.13
Cara Therapeutic stock is currently trading at $4.92 per share. It touched a 52-week high of $13.965 and a 52-week low of $13.965. Analysts tracking the stock have a 12-month average target price of $23.13.
Its 50-day moving average was $9.55 and 200-day moving average was $9.99 The short ratio stood at 14.18 indicating a short percent outstanding of 0%.
Around 1604.6% of the company’s stock are held by insiders while 6548.4% are held by institutions.
Frequently Asked Questions About Cara Therapeutic
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.